Relmada Therapeutics (RLMD) – Hot FDA News
-
Relmada Therapeutics (RLMD) Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder Did Not Achieve Primary Endpoint
-
Relmada Therapeutics (RLMD) Phase 3 RELIANCE III Trial for REL-1017 Did Not Achieve its Primary Endpoint
-
Back to RLMD Stock Lookup